Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

Core Insights - Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing a new class of medicines aimed at correcting abnormal gene expression to treat serious diseases, particularly in oncology [1][3] - The company will participate in two significant conferences: the B. Riley Securities Precision Oncology and Radiopharma Conference and the TD Cowen 45th Annual Health Care Conference, showcasing its Gene Traffic Control platform and broad pipeline [1][2] Company Overview - Foghorn Therapeutics is engaged in discovering and developing medicines that target genetically determined dependencies within the chromatin regulatory system, utilizing its proprietary Gene Traffic Control platform [3] - The company is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system, with multiple product candidates currently in development for oncology [3] Upcoming Events - The company will present at the Synthetic Lethality Panel on February 28, 2025, and at the TD Cowen conference on March 3, 2025, with presentations by President and CEO Adrian Gottschalk [4] - A webcast of the presentations will be available for 90 days on the company's website [2]